MedTrace Logo

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

NCT00723970 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2012-02-08

No results posted yet for this study

Summary

The study was designed to examine the efficacy and tolerability of quetiapine XR for the treatment of women who suffer from depression in the context of the menopausal transition and postmenopausal years. Besides the improvement of depressive symptoms, the investigators are interested in examining the impact of this medication on vasomotor symptoms (hot flashes, night sweats), sleep and overall quality of life.

Conditions

Interventions

DRUG

Quetiapine Extended Release

Quetiapine XR, 150-300 mg QHS, for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Claudio N Soares, MD, PhD · St. Joseph's Healthcare Hamilton, McMaster University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00723970 on ClinicalTrials.gov